![Peter DeMuth](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 2 080 $ al 31/07/2026
Peter DeMuth currently works at Elicio Therapeutics, Inc., as Chief Scientific Officer from 2022.
Dr. DeMuth also formerly worked at Elicio Therapeutics, Inc. (United States), as Chief Scientific Officer from 2022 to 2023.
Dr. DeMuth received his doctorate degree in 2013 from Massachusetts Institute of Technology and undergraduate degree in 2008 from the University of Maryland.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 16/07/2026 | 743 ( 0 % ) | 2 080 $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ELICIO THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/01/2022 |
| Empresas | Cargo | Fin |
|---|---|---|
Elicio Therapeutics, Inc. (United States)
 Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Director Técnico/Científico/I+D | 01/06/2023 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Elicio Therapeutics, Inc. (United States)
Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
University of Maryland
 University of Maryland Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Elicio Therapeutics, Inc.
 Elicio Therapeutics, Inc. BiotechnologyHealth Technology Develops cancer immunotherapies | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
